KIF14在肝细胞癌SMCC-7721获得性耐药机制中的研究

doi:10.11904/j.issn.1002-3070.2022.01.003

实用肿瘤学杂志 ›› 2022, Vol. 36 ›› Issue (1): 14-19.doi: 10.11904/j.issn.1002-3070.2022.01.003

KIF14在肝细胞癌SMCC-7721获得性耐药机制中的研究

王宗文^1,2, 李小东^1,2, 朱乾坤^1,2, 曾世聪^1,2, 翟博^1,2

1.黑龙江省医学科学院(哈尔滨 150001);
2.哈尔滨医科大学附属第四医院肿瘤外科肝胆外科

收稿日期:2021-05-28 修回日期:2021-11-05 出版日期:2022-02-28 发布日期:2022-01-21
通讯作者: 翟博,E-mail:zhaibo_hrbmu@163.com
作者简介:王宗文,男,(1997-),硕士研究生,从事肝癌耐药机制的研究。
基金资助:
黑龙江省医学科学院科研计划项目(编号:201815);哈尔滨医科大学附属第四医院星火计划项目(编号:HYDSYXH201904)

KIF14 in the mechanism of acquired drug resistance in hepatocellular carcinoma SMCC-7721 cells

WANG Zongwen^1,2, LI Xiaodong^1,2, ZHU Qiankun^1,2, ZENG Shicong^1,2, ZHAI Bo^1,2

1. Heilongjiang Academy of Medical Sciences,Harbin 150001,China;
2. Department of Oncology and Hepatobiliary Surgery,The Fourth Affiliated Hospital of Harbin Medical University

Received:2021-05-28 Revised:2021-11-05 Online:2022-02-28 Published:2022-01-21

摘要/Abstract

摘要： 目的探究抑制KIF14与肝细胞癌SMCC-7721对索拉非尼获得性耐药的关系。方法采用浓度梯度法建立肝细胞癌索拉非尼耐药细胞系SMCC-7721-SR,后采用CCK-8法、流式细胞仪验证耐药细胞株的耐药性。在人正常肝细胞LO2、肝细胞癌SMCC-7721及其耐药细胞SMCC-7721-SR中,采用qRT-PCR及Western blot法检测KIF14的表达情况。随后使用KIF14特异性的小干扰RNA(siKIF14)敲低KIF14并通过Western blot法检测KIF14的表达;为探究敲低KIF14后联合索拉非尼对肝细胞癌索拉非尼耐药细胞的影响,采用CCK-8法检测细胞活力、流式细胞仪检测细胞凋亡。结果与LO2相比SMCC-7721中KIF14表达增高(P＜0.01),与SMCC-7721相比SMCC-7721-SR中KIF14表达也增强(P＜0.01);敲低KIF14的表达可协同索拉非尼抑制SMCC-7721-SR的细胞活力、促进细胞凋亡(P＜0.01)。结论 KIF14参与调控SMCC-7721索拉非尼的获得性耐药,抑制KIF14的表达可增强肝细胞癌SMCC-7721-SR对索拉非尼的敏感性。

关键词: 肝细胞癌, 驱动蛋白家族成员14, 索拉非尼, 耐药

Abstract: Objective The objective of this study was to explore the relationship between inhibition of KIF14 and acquired resistance of hepatocellular carcinoma(HCC)SMCC-7721 cells to sorafenib.Methods The concentration gradient method was used to establish the HCC sorafenib-resistant SMCC-7721-SR cell line,and then the CCK-8 method and flow cytometry were used to verify resistant cell properties of the drug-resistant cell line.The qRT-PCR and Western blot assays were used to determine the expression of KIF14 in human normal liver LO2 cells,HCC SMCC-7721 cells and drug-resistant SMCC-7721-SR cells.Subsequently,KIF14-specific small interfering RNA(siKIF14)was used to knock down KIF14 and the KIF14 level was verified by Western blot;in order to explore the effect of knocking down KIF14 combined with sorafenib on HCC sorafenib-resistant cells,the CCK-8 method was used to detect cell viability,and flow cytometry was used to detect cell apoptosis.Results Compared with LO2 cells,the expression of KIF14 in SMCC-7721 cells was increased(P＜0.01),and the expression of KIF14 in SMCC-7721-SR cells was also increased when compared with SMCC-7721 cells(P＜0.01).Knocking down KIF14 expression could synergistically sorafenib inhibit the cell viability of SMCC-7721-SR cells and promote cell apoptosis(P＜0.01).Conclusion KIF14 is involved in the process of HCC and regulates the acquired sorafenib resistance of SMCC-7721 cells.Inhibiting the KIF14 expression could enhance the sensitivity of SMCC-7721-SR cells to sorafenib.

Key words: Hepatocellular carcinoma, KIF14, Sorafenib, Drug resistance

中图分类号:

R735.7

王宗文, 李小东, 朱乾坤, 曾世聪, 翟博. KIF14在肝细胞癌SMCC-7721获得性耐药机制中的研究[J]. 实用肿瘤学杂志, 2022, 36(1): 14-19.

WANG Zongwen, LI Xiaodong, ZHU Qiankun, ZENG Shicong, ZHAI Bo. KIF14 in the mechanism of acquired drug resistance in hepatocellular carcinoma SMCC-7721 cells[J]. Journal of Practical Oncology, 2022, 36(1): 14-19.

参考文献

1 Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
2 Feng RM,Zong YN,Cao SM,et al.Current cancer situation in China:good or bad news from the 2018 Global Cancer Statistics?[J].Cancer Commun(Lond),2019,39(1):22.
3 Zhai B,Sun XY.Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma[J].World J Hepatol,2013,5(7):345-352.
4 Llovet JM,Villanueva A,Lachenmayer A,et al.Advances in targeted therapies for hepatocellular carcinoma in the genomic era[J].Nat Rev Clin Oncol,2015,12(7):408-424.
5 Prieto-Dominguez N,Ordonez R,Fernandez A,et al.Modulation of autophagy by sorafenib:effects on treatment response[J].Front Pharmacol,2016,7:151.
6 Zhu Q,Ren H,Li X,et al.Silencing KIF14 reverses acquired resistance to sorafenib in hepatocellular carcinoma[J].Aging(Albany NY),2020,12(22):22975-23003.
7 Hung PF,Hong TM,Hsu YC,et al.The motor protein KIF14 inhibits tumor growth and cancer metastasis in lung adenocarcinoma[J].PLoS One,2013,8(4):e61664.
8 Ahmed SM,Theriault BL,Uppalapati M,et al.KIF14 negatively regulates Rap1a-Radil signaling during breast cancer progression[J].J Cell Biol,2012,199(6):951-967.
9 Darwiche W,Gomila C,Ouled-Haddou H,et al.Ascorbic acid(vitamin C)synergistically enhances the therapeutic effect of targeted therapy in chronic lymphocytic leukemia[J].J Exp Clin Cancer Res,2020,39(1):228.
10 Llovet JM,Villanueva A,Lachenmayer A,et al.Advances in targeted therapies for hepatocellular carcinoma in the genomic era[J].Nat Rev Clin Oncol,2015,12(7):408-424.
11 Feng J,Dai W,Mao Y,et al.Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1α/PPAR-γ/PKM2-mediated glycolysis[J].J Exp Clin Cancer Res,2020,39(1):24.
12 Xia S,Pan Y,Liang Y,et al.The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma[J].EBio Medicine,2020,51:102610.
13 Chen KF,Chen HL,Tai WT,et al.Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells[J].J Pharmacol Exp Ther,2011,337(1):155-161.
14 Wang ZZ,Yang J,Jiang BH,et al.KIF14 promotes cell proliferation via activation of Akt and is directly targeted by miR-200c in colorectal cancer[J].Int J Oncol,2018,53(5):1939-1952.
15 Zhai B,Jiang X,He C,et al.Arsenic trioxide potentiates the anti-cancer activities of sorafenib against hepatocellular carcinoma by inhibiting Akt activation[J].Tumour Biol,2015,36(4):2323-2334.
16 Zhai B,Hu F,Yan H,et al.Bufalin reverses resistance to sorafenib by inhibiting Akt activation in hepatocellular carcinoma:the role of endoplasmic reticulum stress[J].PLoS One,2015,10(9):e0138485.

[1]	刘菲, 隋红. 基于肿瘤免疫微环境的肝癌分子分型研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 557-561.
[2]	纪雷, 纪道林, 鲍冬冬, 谭刚. lncRNA在肝细胞癌索拉非尼耐药中的最新研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 562-567.
[3]	赵浩然, 李满, 张玉宝. 肝细胞癌相关RNA结合蛋白研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 576-579.
[4]	李娜, 邓茜, 蒋建军. NF-κB信号通路在恶性肿瘤化疗耐药中的作用[J]. 实用肿瘤学杂志, 2021, 35(6): 580-584.
[5]	贺玲, 姚克铖. 糖基磷脂酰肌醇转酰胺酶与肝癌[J]. 实用肿瘤学杂志, 2021, 35(5): 458-461.
[6]	李钰莹, 张悦. Sirtuins在乳腺癌中作用机制的研究进展[J]. 实用肿瘤学杂志, 2021, 35(3): 277-281.
[7]	郭飘婷, 邹阳. LncRNA SOX2OT海绵吸附miR-34a促进SOX2表达增强大肠癌多药耐药[J]. 实用肿瘤学杂志, 2020, 34(5): 398-403.
[8]	陈都, 钱诚. 乳腺癌肿瘤微环境中间质细胞介导的化疗耐药性研究进展[J]. 实用肿瘤学杂志, 2020, 34(4): 382-386.
[9]	梁永琴, 赵宏伟. 抗血管生成药物在铂耐药卵巢癌中的应用进展[J]. 实用肿瘤学杂志, 2020, 34(1): 60-63.
[10]	黄显博, 史庭 , 叶琇锦. 靶向PI3K/AKT/mTOR信号通路治疗急性T淋巴细胞白血病的研究进展[J]. 实用肿瘤学杂志, 2019, 33(5): 451-455.
[11]	曲雁飞, 刘超, 王勃军, 方琳, 张艳桥. CSN6基因在肝细胞癌组织中的表达及临床意义[J]. 实用肿瘤学杂志, 2019, 33(4): 328-333.
[12]	赵凌云, 齐鲁楠, 游雪梅审校. 热休克蛋白70在肝细胞癌中的研究进展[J]. 实用肿瘤学杂志, 2017, 31(6): 528-532.
[13]	孙丽娜, 赵晓迪综述, 卢瑗瑗, 王新审校. LncRNA与胃肠道肿瘤化疗耐药的研究进展[J]. 实用肿瘤学杂志, 2017, 31(5): 448-453.
[14]	曾玉兰,刘洋洋,梁金燕,谷飞飞,刘莉. 免疫检查点抑制剂耐药机制及耐药后治疗策略的研究进展[J]. 实用肿瘤学杂志, 2017, 31(4): 353-358.
[15]	赵孟雷. 番茄红素对人肝癌HepG2细胞增殖和凋亡的影响[J]. 实用肿瘤学杂志, 2017, 31(3): 211-216.

KIF14在肝细胞癌SMCC-7721获得性耐药机制中的研究

KIF14 in the mechanism of acquired drug resistance in hepatocellular carcinoma SMCC-7721 cells

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价